Nephrology Center, Toranomon Hospital, Japan.
Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Japan.
Intern Med. 2022 Oct 15;61(20):3083-3088. doi: 10.2169/internalmedicine.8365-21. Epub 2022 Mar 26.
Lenvatinib, a tyrosine kinase inhibitor (TKI), is a stronger inhibitor of vascular endothelial growth factor receptor, fibroblast growth factor receptors 1 to 4, and platelet-derived growth factor receptor (PDGFR) than other TKIs. We herein report a 77-year-old Japanese woman who received the minimum dose of lenvatinib for treatment of hepatocellular carcinoma. Within one month of starting treatment, she developed severe proteinuria, hypertension, and renal dysfunction. A kidney biopsy showed drug-induced thrombotic microangiopathy, podocytopathy, and polar vasculosis. We also observed damage to the renal tubules, where PDGFR is located. To our knowledge, this is the first report of lenvatinib-induced damage to the renal tubules.
仑伐替尼是一种酪氨酸激酶抑制剂（TKI），它对血管内皮生长因子受体、成纤维细胞生长因子受体 1 至 4 和血小板衍生生长因子受体（PDGFR）的抑制作用强于其他 TKI。本文报告了一例 77 岁日本女性，接受仑伐替尼最低剂量治疗肝细胞癌。开始治疗后一个月内，她出现严重蛋白尿、高血压和肾功能障碍。肾活检显示药物诱导的血栓性微血管病、足细胞病和极性血管病。我们还观察到 PDGFR 所在的肾小管损伤。据我们所知，这是仑伐替尼诱导肾小管损伤的首例报告。
